We are a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain […]

We accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a powerful technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. Biopharmaceutical companies use our proprietary biosimulation software throughout drug discovery and development to inform critical decisions […]

We are leading a revolution in measurement devices for chemical and biochemical analysis. We are democratizing laboratory mass spectrometry instruments with our simple handheld and desktop devices, addressing critical-to-life applications. We are reimagining where Mass Spec technology can be used if it is sufficiently small in size, low in cost, and simple to operate. We […]

While we may pursue an acquisition opportunity in any financial technology business in any geographical location, we intend to focus our search on a target that aligns with the background and experience of Motive in financial technology. We expect to focus primarily on companies that serve five primary sub-sectors of our market segment: Banking & […]

We intend to focus our search on a target business that will benefit from economic globalization, particularly as it affects emerging markets. This would include companies in the agriculture, food and water resources, energy, mining and natural resources, telecommunications, technology, and transportation and logistics sectors in the United States and internationally. Our management and directors’ relationships […]

  Roth CH Acquisition II Co., which we refer to as “we,” “us” or “our company,” is a blank check company incorporated in Delaware and formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities, which […]

We intend to focus our search for an initial business combination on companies within the technology sector, as described below, that are market leaders in industries that we believe are primed for outsized growth, provide mission critical solutions to their customers, and have significant recurring revenue with enterprise valuations in an approximate valuation range of […]

  We have not selected any potential initial business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any potential initial business combination target. While we may pursue an initial business combination with a company in any sector or geography, we intend to focus […]

We currently intend to concentrate our efforts on identifying businesses in the technology, media, and telecommunications (“TMT”) space. Our team includes three former senior executives from The Walt Disney Company (NYSE: DIS) (“Disney”): Thomas Staggs, our director and the chairperson of the Strategic Advisory Committee; Kevin Mayer, who will serve as a strategic advisor as of […]

(Note: This is not a traditional IPO. Roblox went public through a direct listing on the New York Stock Exchange. The NYSE set a reference price of $45 for the Class A common stock on March 9, 2021, when the direct listing was priced. The stock started trading on the NYSE on March 10, 2021. Background: […]